Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes.
Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin.
Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 504 S Rosa Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- endsulin.com
- Keywords
- Sun Prairie.
- HQ
- Madison, Wisconsin
Endsulin Questions
Endsulin's website is endsulin.com
Endsulin's LinkedIn profile is https://www.linkedin.com/company/endsulin
Endsulin has
4 employees.
View email and phone details for 4
employees at Endsulin.
Endsulin's industry is
Biotechnology Research
Endsulin's categories are Biotechnology Research
Endsulin's founding year is 2016
